貝達藥業(300558.SZ):收到浙江貝達醫藥100%股權第二期股權轉讓款
格隆匯9月30日丨貝達藥業(300558.SZ)公佈,公司第三屆董事會第七次會議和2020年第二次臨時股東大會分別於2020年6月12日、2020年7月1日審議通過《關於出售貝達醫藥科技100%股權暨關聯交易的議案》,同意公司以2.51億元向寧波凱銘創新科技有限公司(以下簡稱“凱銘創新”)出售持有的浙江貝達醫藥科技有限公司100%股權。凱銘創新系由公司實際控制人丁列明博士控制的公司,本次交易構成關聯交易。
前述第一期7543.905萬元股權轉讓款及標的股權的交割工作已於2020年8月完成。截至本公告日,公司也已收到第二期1.76億元股權轉讓款和標的公司歸還的全部借款本息,標的公司不存在佔用上市公司資金的情況。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.